Olesoxime

Olesoxime is the lead member of a family of cholesterol-oximes discovered by screening for small molecules that promote the survival of purified motor neurons deprived of neurotrophic factors ^[1]. Structurally it resembles cholesterol, which allows it to concentrate in membranes and specifically at the outer mitochondrial membrane, where its molecular targets reside. Rather than acting as a classical electron-shuttle quinone like CoQ10, it exerts its effect by stabilizing mitochondrial membrane behavior and preventing the pathological opening of the mitochondrial permeability transition pore, an event that commits stressed cells to apoptosis or necrosis ^[1].

The compound is orally active, crosses the blood-brain barrier, and was well tolerated in early clinical testing, which earned it orphan drug status for amyotrophic lateral sclerosis in the United States and for spinal muscular atrophy in the European Union ^[1]. In a randomized, double-blind, placebo-controlled phase 2 trial in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy, olesoxime did not meet its primary motor-function endpoint by conventional significance, but secondary analyses suggested it might help maintain motor function over twenty-four months, prompting interest in its use alongside other disease-modifying agents ^[2].

Preclinical breadth is a notable feature of the molecule: beyond motor neuron disease, it has shown protective effects in models of Huntington disease, Parkinson disease, peripheral neuropathy, and other conditions, effects attributed to its actions on oxidative stress, permeability transition, calcium handling, and cholesterol homeostasis ^[3]. Its binding partners TSPO and VDAC link it to mitochondrial calcium regulation, and reduction of calpain overactivation has been proposed as an additional downstream benefit ^[3]. Olesoxime therefore stands as an instructive example of a mitochondria-targeted neuroprotectant that works at the permeability transition pore rather than in the respiratory chain.

Moderate clinical evidence; extensive preclinical neuroprotection data, pivotal endpoints not met

Olesoxime was consistently well tolerated across its clinical program, with an adverse event profile in the spinal muscular atrophy trial that closely resembled placebo; the most frequent events were pyrexia, cough, nasopharyngitis, and vomiting, and the two deaths recorded were not deemed treatment-related ^[2]. Its oral bioavailability, brain penetration, and benign tolerability were repeatedly cited as strengths. As with other investigational neuroprotectants, its safety in long-term healthy-adult use outside supervised trials is unknown, and no consumer formulation exists.

Olesoxime was discovered by the French biotechnology company Trophos, which identified the cholesterol-oxime series through a motor-neuron survival screen. It progressed to phase 2 and 3 testing in amyotrophic lateral sclerosis and to a phase 2 trial in spinal muscular atrophy conducted with AFM Telethon. Roche later acquired the asset; when the primary spinal muscular atrophy endpoint was not met and newer genetic therapies emerged, active development wound down, leaving olesoxime as a well-characterized but ultimately shelved neuroprotective candidate.

Olesoxime enjoys a solid scientific reputation as a clean, well-tolerated, mechanistically distinct neuroprotectant, and it is frequently cited in reviews of mitochondrial permeability transition pore pharmacology. Its clinical trials did not translate into an approved therapy, so in practical terms it is regarded as a promising concept that fell short of endpoints. It is essentially unknown as a nootropic or supplement and should be viewed strictly as a research and clinical-development compound.